

Resource Summary Report

Generated by [RRID](#) on Sep 8, 2026

Rh4

RRID:CVCL_5916

Type: Cell Line

Proper Citation

RRID:CVCL_5916

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5916

Proper Citation: RRID:CVCL_5916

Description: Cell line Rh4 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Alveolar rhabdomyosarcoma

Defining Citation: [PMID:7536457](#), [PMID:8275086](#), [PMID:9823299](#), [PMID:19235922](#), [PMID:23578105](#), [PMID:23665679](#), [PMID:23882450](#), [PMID:25806826](#), [PMID:25894527](#), [PMID:36768928](#)

Comments: Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Rh4

Synonyms: RH4, Rh-4, SJRH-4, SJRH4, SJ-RH4, SJ-Rh 4

Cross References: BTO:BTO_0005381, EFO:EFO_0022574, cancercellines:CVCL_5916, Cell_Model_Passport:SIDM01349, Cosmic:687959, Cosmic:801756, Cosmic:1037295, Cosmic:1048108, Cosmic:1097744, Cosmic:1104559, Cosmic:1108738, Cosmic:1309336, Cosmic:2820088, DepMap:ACH-001765, GEO:GSM219756, GEO:GSM1012758, Lonza:486, PRIDE:PXD000589, PRIDE:PXD039480, Wikidata:Q54950344

ID: CVCL_5916

Record Creation Time: 20220427T221459+0000

Record Last Update: 20260905T182216+0000

Ratings and Alerts

No rating or validation information has been found for Rh4.

No alerts have been found for Rh4.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 13 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Tian M, et al. (2026) Targeted antibody-drug conjugates for rhabdomyosarcoma and other FGFR4-expressing cancers. Cell reports. Medicine, 7(7), 102922.

Rask GC, et al. (2025) Seclidemstat (SP-2577) Induces Transcriptomic Reprogramming and Cytotoxicity in Multiple Fusion-Positive Sarcomas. Cancer research communications, 5(9), 1584.

Oles AR, et al. (2025) MyoD is essential in rhabdomyosarcoma by promoting survival through differentiation and CYLD. iScience, 28(8), 113149.

Mendes EA, et al. (2025) RUNX2 inhibition disrupts a PAX3::FOXO1-RUNX2 feed-forward loop and dismantles oncogenic gene programs in fusion-positive rhabdomyosarcoma. bioRxiv : the preprint server for biology.

Toure MA, et al. (2025) Targeted degradation of CDK9 potentially disrupts the MYC-regulated network. Cell chemical biology, 32(4), 542.

Danielli SG, et al. (2024) Evaluation of the Role of AXL in Fusion-positive Pediatric Rhabdomyosarcoma Identifies the Small-molecule Inhibitor Bemcentinib (BGB324) as Potent Chemosensitizer. Molecular cancer therapeutics, 23(6), 864.

Danielli SG, et al. (2023) Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevance. Science advances, 9(6), eade9238.

Milton CI, et al. (2022) FGF7-FGFR2 autocrine signaling increases growth and chemoresistance of fusion-positive rhabdomyosarcomas. Molecular oncology, 16(6), 1272.

Polyanskaya SA, et al. (2022) SCP4-STK35/PDIK1L complex is a dual phospho-catalytic signaling dependency in acute myeloid leukemia. *Cell reports*, 38(2), 110233.

Malone CF, et al. (2021) Selective Modulation of a Pan-Essential Protein as a Therapeutic Strategy in Cancer. *Cancer discovery*, 11(9), 2282.

Gryder BE, et al. (2020) Measurement of differential chromatin interactions with absolute quantification of architecture (AQuA-HiChIP). *Nature protocols*, 15(3), 1209.

Marques JG, et al. (2020) NuRD subunit CHD4 regulates super-enhancer accessibility in rhabdomyosarcoma and represents a general tumor dependency. *eLife*, 9.

Sanna L, et al. (2019) "Verteporfin exhibits anti-proliferative activity in embryonal and alveolar rhabdomyosarcoma cell lines". *Chemico-biological interactions*, 312, 108813.